« Back
Home /
WYC-210

WYC-210

Item no.	HY-136554-25mg
Manufacturer	MedChem Express
CASRN	2131803-93-3
Amount	25 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.18
Citations	[1]Cao, Xin, et al. Preparation of the retinoid compound and their application as anticancer agents. WO2017152725A1.
Smiles	O=C(C1=CN=C(C#CC2=CC=C3C(C(C)(C)CCS3=O)=C2)N=C1)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	2131803-93-3
Similar products	2131803-93-3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Drug Derivative
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	340.40
Product Description	WYC-210, a Tazarotene derivative, is a retinoid compound with lower anticancer activity[1]. WYC-210 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Others
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-136554-25mg-safety-datasheet.pdf